Miglitol (Migtor (50 mg)) is an oral anti-diabetic drug (alpha-glucosidase inhibitor), prescribed for type 2 diabetes either alone or with other medications. It slows down carbohydrates metabolism.
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak with a healthcare professional.
In which conditions should Migtor (50 mg) be avoided?
Contraindicated in patients with diabetic ketoacidosis (high blood glucose with the presence of ketones in the urine), inflammatory bowel disease, intestinal blockage, prolonged intestinal diseases and hypersensitivity.
Advertisement
What are the Precautions needed with Migtor (50 mg)
Caution should be exercised in patients with history of decreased level of sugar in blood, kidney impairment, liver disease, any allergy, who are taking other medications, during pregnancy and breastfeeding.
Are there any additional Precautions?
Monitor blood sugar level regularly.
At What Temperature Should it be Stored?
Store it at room temperature (15-30°C), and in an airtight container.
A: Migtor (50 mg) has been shown to help with weight loss. Migtor (50 mg) is more effective than other alpha-glucosidase inhibitors at lowering patient body weight(1✔✔Trusted Source Miglitol prevents diet-induced obesity by stimulating brown adipose tissue and energy expenditure independent of preventing the digestion of carbohydrates
A: Migtor (50 mg) alone does not cause hypoglycemia(low blood sugar). Migtor (50 mg) may cause hypoglycemia when combined with other hypoglycemic agents(2✔✔Trusted Source Miglitol
A: Migtor (50 mg) should be taken orally with food. Migtor (50 mg) is usually taken three times per day with the first bite of a meal(3✔✔Trusted Source Miglitol
A: Migtor (50 mg) may be beneficial in elderly patients. There are no dosage adjustments needed in elderly patients, those with hepatic impairment, or those with mild to moderate renal insufficiency(4✔✔Trusted Source Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus
A: Migtor (50 mg) is not recommended for patients with diabetic ketoacidosis (high blood glucose with the presence of ketones in the urine), inflammatory bowel disease, intestinal blockage, prolonged intestinal diseases and hypersensitivity(5✔✔Trusted Source Information about Miglitol
Medindia adheres to strict ethical publishing standards to provide accurate, relevant, and current health content. We source our material from reputable places such as peer-reviewed journals, academic institutions, research bodies, medical associations, and occasionally, non-profit organizations. We welcome and value audience feedback as a part of our commitment to health literacy and informed decision-making.
1. Miglitol prevents diet-induced obesity by stimulating brown adipose tissue and energy expenditure independent of preventing the digestion of carbohydrates - (https://pubmed.ncbi.nlm.nih.gov/23995917/#: )
4. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus - (https://pubmed.ncbi.nlm.nih.gov/10776834/ )
5. Information about Miglitol - (https://www.medindia.net/doctors/drug_information/miglitol.htm )
Search for Drugs/Medicines
Disclaimer :
Medindia updates the prices regularly, however, there may be slight discrepancies in the prices displayed. This can be due to the following reasons:
Difference in GST/local taxes
Change in price by the company
Updation of price information may not have happened at the right time
For the above reasons, Medindia cannot be held liable for any action taken based on the information provided by its website. The purpose of this website is to provide initial guidance only and it does not intend to replace professional medical opinion in any manner whatsoever. Please also be aware that Medindia does not buy or sell medication.
Post a Comment
Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
